Needham analyst Mike Matson raised his price target on AtriCure to $32 and kept his Buy rating, saying he has greater confidence in the company's ability to sustain its revenue growth. The analyst cites the "strong Open-Heart Ablation growth, strong AtriClip growth driven by new products with higher prices", conservative guidance, and easing comps in the second half of this year. The analyst also anticipates next week's analyst meeting to serve as a catalyst in the near-term and the results from its CONVERGE trial next year as a catalyst for the longer term.

Oppenheimer analyst Suraj Kalia upgraded AtriCure to Outperform from Perform with a $32 price target.